ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36775
-0.01%
Bitcoin
60,888.23
0.15%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN

Arvinas (ARVN)

Arvinas Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARVN
DateTimeSourceHeadlineSymbolCompany
05/09/20243:42PMGlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
05/07/20243:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
05/07/20246:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/07/20246:00AMGlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
05/02/20246:00AMGlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
04/24/20243:30PMGlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
04/11/20246:00AMGlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
03/18/20243:40PMGlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
03/04/20246:00AMGlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
02/27/20245:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20243:46PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
02/27/20246:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
02/27/20246:00AMGlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
02/20/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
02/20/20243:05PMGlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
02/20/20246:00AMGlobeNewswire Inc.Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseNASDAQ:ARVNArvinas Inc
02/14/20247:00AMGlobeNewswire Inc.Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast CancerNASDAQ:ARVNArvinas Inc
02/13/20247:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARVNArvinas Inc
02/06/20245:45AMGlobeNewswire Inc.Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:ARVNArvinas Inc
02/01/20243:30PMGlobeNewswire Inc.Arvinas to Present at 6th Annual Guggenheim Biotechnology ConferenceNASDAQ:ARVNArvinas Inc
01/16/20244:01PMGlobeNewswire Inc.Arvinas Appoints Jared Freedberg as General CounselNASDAQ:ARVNArvinas Inc
01/16/20243:03PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARVNArvinas Inc
01/08/20243:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
01/08/20246:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
12/08/20238:16AMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ARVNArvinas Inc
12/06/20236:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
12/05/20239:52PMGlobeNewswire Inc.Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
 Showing the most relevant articles for your search:NASDAQ:ARVN

Your Recent History

NASDAQ
RNAZ
TransCode Therapeutics
USOTC
PHIL
PHI (PK)
USOTC
FMCC
Federal Home Loan Mortgage (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
GVSI
Good Vibrations Shoes (PK)
NASDAQ
COOP
Mr Cooper
USOTC
AXXA
Exxe (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
RONN
Ronn Motor (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
RVNC
Revance Therapeutics
USOTC
GDVM
Global Developments (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved